Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
Abstract Infliximab dosage de‐escalation without prior knowledge of drug concentrations may put patients at risk for underexposure and trigger the loss of response. A single‐model approach for model‐informed precision dosing during infliximab maintenance therapy has proven its clinical benefit in pa...
Saved in:
Main Authors: | Wannee Kantasiripitak (Author), An Outtier (Author), Sebastian G. Wicha (Author), Alexander Kensert (Author), Zhigang Wang (Author), João Sabino (Author), Séverine Vermeire (Author), Debby Thomas (Author), Marc Ferrante (Author), Erwin Dreesen (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
by: Ruben Faelens, et al.
Published: (2021) -
Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
by: Wannee Kantasiripitak, et al.
Published: (2020) -
Infliximab in inflammatory bowel disease
by: Konstantinos Papamichael, et al.
Published: (2019) -
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
by: Christina Schräpel, et al.
Published: (2021) -
Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
by: Dahham Alsoud, et al.
Published: (2022)